Living with non-small cell lung cancer

Stories from people navigating non-small cell lung cancer — diagnosis, treatment, caregiving, and the ordinary days in between.

3 stories

Lung cancer tissue slide beside a molecular sequencing report highlighting an ERBB2 mutation

Oncology

Sevabertinib Approval Narrows HER2-Mutated NSCLC Use

FDA accelerated approval applies to previously treated, advanced non-squamous NSCLC with qualifying activating mutations in the HER2 tyrosine kinase domain—not every ERBB2 alteration.

Rayan Salih · September 16, 2026 · 6 min

Lung tumor specimen beside a genomic sequencing report highlighting an ERBB2 kinase-domain mutation.

Oncology

Sevabertinib Makes HER2 Testing Actionable in NSCLC

The FDA granted accelerated approval to sevabertinib for adults with advanced nonsquamous NSCLC harboring activating HER2 tyrosine kinase domain mutations, making validated genomic identification central to treatment selection.

Rayan Salih · 6 min read

Resected lung cancer specimen slides beside a molecular pathology report identifying an ALK alteration

Oncology

Ensartinib Lowers Recurrence Risk in ALK-Positive NSCLC

A phase 3 trial found that daily ensartinib substantially prolonged disease-free survival after chemotherapy and complete resection of stage IB-IIIB ALK-positive NSCLC.

Dr. Abu Bakar · 6 min read

Other conditions

One story a day

The story of the day, in your inbox

One health journey each morning — no advice, no alarm, just company for the road.